Acute lung injury (ALI) is a severe inflammatory condition marked by disruption of the alveolar-capillary barrier and impaired gas exchange. Emerging evidence implicates cathepsin L as a key contributor to ALI pathogenesis through protease-mediated tissue damage and amplification of inflammatory responses. Researchers from Zhejiang University of Technology reported the development of a new cathepsin L inhibitor designed for the treatment of ALI.
Acute lung injury (ALI) is a severe condition marked by uncontrolled lung inflammation and tissue damage, often leading to respiratory failure. Excessive immune activation recruits neutrophils that release pro-inflammatory cytokines, including IL‑6 and TNF‑α, while generating reactive oxygen species (ROS) that damage DNA and trigger cell death. Thus, controlling inflammation and limiting ROS are key strategies to prevent ALI.
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are severe respiratory conditions characterized by complex and incompletely understood pathophysiological mechanisms. Increasing evidence suggests that mitochondrial dysfunction contributes significantly to ALI pathogenesis.
Activation of the α7 nicotinic acetylcholine receptor may be therapeutically useful against acute lung injury by suppressing expression of pro-inflammatory genes.
The metabotropic nucleotide receptor P2Y14 shows strong potential as a therapeutic target against various inflammatory diseases, particularly acute lung injury, yet the small-molecule inhibitors described so far have performed poorly in preclinical studies.
Shanghai Yidi Biotechnology Co. Ltd. has disclosed neutrophil elastase (ELANE; leukocyte elastase) inhibitors reported to be useful for the treatment of pain and respiratory tract inflammation.
Several lung conditions, such as acute lung injury, require the targeted delivery of pharmacological agents to the lower lung. However, the administration of complex biologics, such as anti-inflammatory cytokine mRNA, to the injury site in the lower lungs is particularly challenging, frequently leading to poor specificity and uneven distribution.
Researchers from Kevirx Inc. and collaborators have described the use of KVX-053, a PTP4A3 inhibitor aimed to be used for the prevention of COVID-19-associated cute lung injury (ALI).
Researchers from Wenzhou Medical University and affiliated organizations presented the discovery and preclinical characterization of a novel myeloid differentiation primary response 88 (MyD88) inhibitor for the treatment of acute lung injury (ALI).
